Morgan Stanley Maintains Overweight Rating for Zentalis Pharma: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Morgan Stanley has maintained its Overweight rating for Zentalis Pharma (NASDAQ:ZNTL) but lowered its price target from $55.00 to $38.00. Zentalis Pharma's shares are currently trading down 4.33% at $11.94 per share. A move to the new price target would represent a 218.26% increase from the current share price.
November 07, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has maintained its Overweight rating for Zentalis Pharma but lowered its price target. This could potentially lead to increased volatility in the short term.
The news of Morgan Stanley maintaining its Overweight rating but lowering the price target for Zentalis Pharma could lead to increased volatility in the stock's price. Investors may interpret this as a mixed signal, causing uncertainty and potentially leading to price fluctuations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100